GlycoErase™ ST3GAL2 Knockout Human Bladder Cancer Cell 5637 (CAT#: GLJF-0525-JF87)

Description	The ST3GAL2 knockout 5637 cell line, lacking ST3 beta-galactoside alpha-2,3-sialyltransferase 2 catalyzing sialylation in Golgi, enables the study of sialylation disruption in bladder carcinoma, potentially affecting alpha-2,3-sialylation of glycans, cell surface sialylation, and sialic acid mediated functions.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:3~1:6
Cell Line	5637
Primary Disease	Bladder Urothelial Carcinoma
Lineage	Bladder/Urinary Tract

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	FBS & Penicillin/Streptomycin & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ST3GAL2
Full Name	ST3 Beta-galactoside alpha-2,3-sialyltransferase 2
Alternative Name	ST3GALII, ST3GalA.2, SIAT4B
Location	16q22.1
Gene ID	6483
Summary	Catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates, similar to sialyltransferase 4A; found in the Golgi and can be proteolytically processed.